Bisphosphonates for osteoporosis--where do we go from here?

N Engl J Med. 2012 May 31;366(22):2048-51. doi: 10.1056/NEJMp1202619. Epub 2012 May 9.

Authors

Marcea Whitaker¹, Jia Guo, Theresa Kehoe, George Benson

Affiliation

¹ Division of Reproductive and Urologic Products, Office of New Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, USA.

PMID: 22571168
DOI: 10.1056/NEJMp1202619

No abstract available

MeSH terms

Bone Density / drug effects
Bone Density Conservation Agents / pharmacology
Bone Density Conservation Agents / therapeutic use*
Diphosphonates / pharmacology
Diphosphonates / therapeutic use*
Fractures, Bone / epidemiology
Fractures, Bone / prevention & control*
Humans
Osteoporosis / drug therapy*
Risk
Spinal Fractures / epidemiology
Spinal Fractures / prevention & control

Substances

Bone Density Conservation Agents
Diphosphonates